Curated News
By: NewsRamp Editorial Staff
June 08, 2026
TransCode Therapeutics to Host First Live R&D Webcast on June 18, 2026
TLDR
- TransCode's Phase 2a trial for TTX-MC138 could give investors an edge in the oncology market.
- TransCode will host a webcast to detail its Phase 2a trial of TTX-MC138 targeting microRNA-10b in colorectal cancer.
- TransCode's RNA therapeutic aims to improve outcomes for patients with metastatic cancers, offering hope for better treatments.
- TransCode's TTX-MC138 targets microRNA-10b, a unique biomarker of metastasis, distinguishing it from other cancer therapies.
Impact - Why it Matters
This news matters because it provides a window into TransCode's progress with TTX-MC138, a novel RNA therapeutic targeting metastatic cancer. For investors and patients, the Phase 2a trial results could signal a breakthrough in treating colorectal cancer and other aggressive tumors. The webcast offers transparency and insight into the company's strategy and pipeline, which could influence investment decisions and patient hope for new treatments.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) is set to host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific, and clinical updates across its development pipeline. The webcast will focus on the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, a key milestone for the clinical-stage company. TransCode specializes in immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, with TTX-MC138 targeting metastatic tumors that overexpress microRNA-10b, a unique biomarker of metastasis. The event will also cover portfolio updates and the broader investment thesis, offering investors a comprehensive look at the company’s progress and future direction.
The news release, distributed by InvestorWire, highlights TransCode’s commitment to advancing its pipeline of first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells. InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, provides press release syndication and enhanced distribution services to reach investors, influencers, and the public. The full press release is available at https://ibn.fm/u5AfW, and latest updates on RNAZ can be found in the company’s newsroom at https://ibn.fm/RNAZ. TransCode’s focus on microRNA-10b as a target represents a novel approach in oncology, potentially offering new hope for patients with hard-to-treat metastatic cancers.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode Therapeutics to Host First Live R&D Webcast on June 18, 2026
